Genetic Testing Methodology

Overview

Genetic testing in ophthalmology used to mean confirming one suspected mutation at a time. Now a single order can screen hundreds of candidate genes at once, but that expanded reach comes with real technical trade-offs. No single test detects every category of pathogenic variant. Short-read sequencing struggles with repetitive regions and large rearrangements, standard exome sequencing misses most non-coding variants, and even whole genome sequencing often needs functional confirmation by RNA sequencing for variants that alter splicing rather than protein sequence directly. Choosing the right test, and recognizing when a negative result doesn't actually rule out a genetic cause, requires knowing what each technology is built to find.

What happens after sequencing matters just as much. A raw list of variants has to be filtered against population databases and weighed against a formal evidence framework before it becomes a clinical answer. The sections below cover the sequencing and structural technologies first, then the classification framework, then how both feed into real clinical decisions: counseling, cascade testing, and reproductive planning.

Sequencing Modalities

Sanger Sequencing

Sanger sequencing, also called chain-termination sequencing, is still the gold standard for confirming one already-suspected variant. Dideoxynucleotide triphosphates (ddNTPs) terminate DNA chain extension at specific bases; the resulting fragments, sorted by length on capillary electrophoresis, are read out fluorescently to reconstruct the sequence. The method is highly accurate for small, targeted regions but doesn't scale to genome-wide analysis. That limitation is exactly why it survives today as a confirmatory step after a higher-throughput method has already flagged a candidate variant, not as a first-line discovery tool.

Next-Generation (Massively Parallel) Sequencing

Next-generation sequencing (NGS) differs from Sanger sequencing by running massively parallel sequencing of millions of DNA fragments at once, using platforms like Illumina (sequencing by synthesis) or Ion Torrent (sequencing by detecting hydrogen ion release). That parallelism is what makes sequencing an entire exome or genome practical, at a fraction of the cost and turnaround time Sanger sequencing would need for the same scope. NGS is the underlying technology behind every sequencing test described below except Sanger itself.

Whole Exome Sequencing

Whole exome sequencing (WES) targets only the protein-coding exons, roughly 1–2% of the genome, spanning around 20,000 genes, rather than the whole genome. Most known Mendelian disease-causing variants fall within coding sequence, so WES still captures the majority of clinically actionable findings at substantially lower cost than whole genome sequencing. That trade-off makes it the current workhorse for diagnosing undiagnosed genetic disease broadly, ophthalmology included.

Targeted Gene Panels vs. Whole Genome Sequencing

When a patient has clear, well-defined features of a specific disease category, retinitis pigmentosa (RP) and its more than 70 known causative genes being the classic example, a targeted gene panel restricted to those genes is generally the preferred first-line test over whole genome sequencing (WGS). Panels cover the genes that actually matter more deeply, which improves detection of low-level mosaicism within them, and their more focused bioinformatic analysis produces fewer incidental findings than WGS. In a condition with well-characterized genetic architecture like RP, panels reach diagnostic yields of roughly 50–70%, at substantially lower cost than WGS.

Long-Read Sequencing for Structural Variants

Standard short-read NGS platforms struggle with highly repetitive genomic regions and large structural rearrangements. RPGR ORF15, the most mutation-rich region of the most important X-linked RP gene, is the paradigm ophthalmic example: a purine-rich, highly repetitive, hypermutable sequence that short reads can't reliably align or assemble. Long-read platforms (Oxford Nanopore, PacBio) generate individual reads spanning 10–100 kilobases rather than a few hundred base pairs. They can span these repetitive regions directly, resolve complex repeat structures, phase variants as occurring in cis or trans on the same or different alleles, and detect structural rearrangements and tandem repeat expansions, relevant to conditions like myotonic dystrophy, that short-read approaches routinely miss.

RNA Sequencing for Splicing-Variant Detection

A substantial share of unsolved inherited retinal disease cases, especially those tied to ABCA4, USH2A, and CEP290 (the single most common LCA gene), carry deep intronic variants that create cryptic splice sites. None of these fall within the coding sequence that exome sequencing captures, so they're missed on a standard exome. Whole genome sequencing can find them, and RNA sequencing can then functionally confirm them by directly showing the aberrant transcript the abnormal splicing produces. That confirmation is often essential both for establishing pathogenicity and for qualifying a patient for splicing-targeted gene therapy.

Chromosomal Microarray & FISH

Array Comparative Genomic Hybridization (aCGH) / Chromosomal Microarray

Chromosomal microarray analysis (CMA, performed via array CGH or SNP arrays) is built to detect copy number variants, deletions and duplications, across the genome by comparing patient DNA against reference DNA hybridized to thousands of probes. It resolves deletions and duplications at considerably higher resolution than a traditional karyotype. What it cannot do is detect balanced translocations, where no net genetic material is gained or lost, or point mutations. CMA is purpose-built for dosage changes, not sequence changes.

Fluorescence In Situ Hybridization (FISH)

FISH uses fluorescently labeled DNA probes complementary to specific chromosomal regions to directly visualize whether those regions are present, absent, or rearranged in metaphase or interphase cells. In ophthalmic genetics it detects chromosomal deletions, such as 13q14 in retinoblastoma or 11p13 in WAGR syndrome, along with duplications, translocations, and aneuploidy. It provides targeted, high-confidence confirmation of a specific structural abnormality as a complement to NGS-based copy number analysis, and is especially useful when a specific chromosomal region is already strongly suspected on clinical grounds.

Multiplex Ligation-Dependent Probe Amplification (MLPA)

MLPA fills a gap neither chromosomal microarray nor standard NGS panel sequencing covers well: single- or multi-exon deletions and duplications within one specific gene. Exon-specific probes are ligated and PCR-amplified alongside control probes from elsewhere in the genome, and the resulting peak heights show whether a given exon sits at normal, reduced, or doubled dosage. This matters directly for inherited retinal disease. A meaningful share of patients who carry only one detected pathogenic variant in genes such as EYS or USH2A on NGS panel testing turn out to carry a second, exon-level deletion or duplication that panel sequencing missed entirely. MLPA is the test built to find it.

Variant Classification

The ACMG/AMP Framework

The American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) framework sorts every identified variant into one of five tiers: Class 1 (benign), Class 2 (likely benign), Class 3 (variant of uncertain significance), Class 4 (likely pathogenic), and Class 5 (pathogenic). Diagnosis, genetic counseling, and cascade testing of relatives are all based specifically on Classes 4 and 5. Classes 1 through 3 are generally not actioned clinically, though a Class 3 variant may still be reclassified later as more evidence accumulates.

Variant of Uncertain Significance (VUS)

A VUS designation means the current evidence isn't sufficient to call a variant pathogenic or benign. It's a statement about where the evidence stands today, not a permanent classification. As more data accumulates from population databases, functional studies, and family segregation analysis (does the variant track with disease within a specific pedigree, or not), a VUS can move in either direction. That's why genetic testing reports are, in principle, worth periodically re-reviewing rather than treating as a single fixed answer: a VUS reported years ago may since have been reclassified as pathogenic or benign.

Population Allele Frequency Filtering: gnomAD

The Genome Aggregation Database (gnomAD) holds allele frequency data from well over 100,000 exomes and tens of thousands of genomes, and it's used during variant interpretation to filter out variants too common in the general population to plausibly cause a rare, severe Mendelian disease. As a general rule, a minor allele frequency above 1% is considered too common to be pathogenic for a rare severe Mendelian eye disease. Lower thresholds, 0.1% or 0.5%, apply for especially severe or recessive conditions, where even a modestly elevated population frequency would be implausible given how rare the disease actually is. This single filter removes the large majority of detected variants from further consideration.

Variant Databases: ClinVar and LOVD

Publicly accessible variant databases such as ClinVar and the Leiden Open Variation Database (LOVD), along with disease-specific resources like RETNET for retinal dystrophies, let a lab check whether a given variant has already been reported as pathogenic or benign in other affected individuals. This is one of the key lines of evidence in ACMG/AMP classification, corresponding to criteria like PS1/PM5. Concordant pathogenic classifications from multiple independent submitters strengthen the case for clinical significance considerably; conflicting interpretations across submitters do the opposite, pushing a variant toward, or keeping it at, VUS status.

Clinical Application

Cascade Genetic Testing

Cascade testing means systematically offering targeted testing for a known familial mutation to at-risk relatives, typically first-degree relatives first and second-degree relatives after, rather than running a broad, expensive test on everyone in the family. It's the most cost-effective strategy for finding at-risk individuals before symptoms appear. In ophthalmology it matters most for retinoblastoma and hereditary optic neuropathy families, where identifying a mutation carrier early changes surveillance intensity long before any clinical sign would otherwise prompt testing.

Germline RB1 Testing and Heritable Retinoblastoma

When a child is diagnosed with retinoblastoma, testing both the tumor DNA and the germline (blood) DNA for RB1 mutations is essential. A pathogenic RB1 variant found in blood DNA confirms heritable retinoblastoma: every somatic cell in the child carries the first "hit," consistent with Knudson's two-hit model. That finding has direct implications for the whole family. The proband carries a 50% risk of transmitting the mutation to each future child, and a sibling carries up to a 50% risk of being a carrier if a parent carries the mutation (much lower when the proband's mutation arose de novo), which is why cascade testing of first-degree relatives is essential. A mutation found only in the tumor, not in blood, points to purely somatic disease without that same familial recurrence risk.

X-Linked Inheritance Risk Counseling: RPGR

Genetic counseling for a family with X-linked RP caused by an RPGR mutation should tell the proband's sisters that they carry roughly a 50% prior probability of being carriers, assuming their mother is the source of the mutation. That number follows directly from the basic rule of X-linked inheritance: each daughter of a carrier mother has a 50% chance of inheriting the mutant X. Targeted mutation testing is what refines that prior probability toward essentially 0% or 100%.

Reduced Penetrance in Genetic Counseling: PRPF31

Counseling around an autosomal dominant inherited retinal dystrophy with reduced penetrance, PRPF31-related RP being the canonical example, requires spelling out that some mutation carriers stay completely unaffected clinically yet can still transmit the mutation and have affected children. The practical consequence is direct: a negative family history does not reliably exclude autosomal dominant inheritance in a PRPF31 family, since an unaffected, mutation-carrying parent can still be the source of disease in their children. That nuance changes how a seemingly negative pedigree should actually be read.

Preimplantation Genetic Testing (PGT-M)

Preimplantation genetic testing for monogenic disease (PGT-M, formerly preimplantation genetic diagnosis or PGD) lets couples at high risk of transmitting a known inherited condition, autosomal dominant retinoblastoma or autosomal recessive RP among them, test embryos created via IVF before implantation and select only unaffected embryos for transfer. At-risk couples can avoid an affected pregnancy altogether this way, without needing prenatal diagnosis and termination later in an already-established pregnancy.

Diagnostic Yield and the Role of Electrophysiology

The molecular diagnostic yield of genetic testing in inherited retinal disease, the proportion of tested patients in whom a pathogenic or likely pathogenic variant is actually identified and explains the phenotype, varies considerably by disease subtype: roughly 75% in LCA, 55–65% in RP, and as high as 90% in Stargardt disease. That spread mostly reflects how well each condition's genetic architecture has been characterized. Electroretinography (ERG) and other visual electrophysiology remain essential alongside genetic testing rather than obsolete because of it, since they supply functional (phenotypic) data that genetic testing alone can't: a rod-dominated pattern of loss suggests RP, a cone-dominated pattern suggests cone-rod dystrophy, and a negative-ERG pattern suggests CSNB. That functional data directs which gene panel is even appropriate to order, and it can independently support or challenge the clinical significance of a genetic finding once it comes back.

Related Topics

Continue exploring Basic Sciences: